Evaluation of efficacy and safety of a metronomic/anti-angiogenic regimen of low-dose oral cyclophosphamide, thalidomide, and dexamethasone in pts with chemotherapy-resistant, castration-refractory prostate cancer in Iran.

M. Salimichokami,S. Aminian,M. Ayati,M. Sanadi-Zadeh

Evaluation of efficacy and safety of a metronomic/anti-angiogenic regimen of low-dose oral cyclophosphamide, thalidomide, and dexamethasone in pts with chemotherapy-resistant, castration-refractory prostate cancer in Iran.

2010

M. Salimichokami
S. Aminian
M. Ayati
M. Sanadi-Zadeh

e15091 Background: Many studies have suggested the efficacy of metronomic/anti-angiogenic regimens in metastatic epithelial human malignancies. This has special relevance to cancers in which microv...

Keywords:

Dexamethasone
Oncology
Refractory
Pathology
Castration
Prostate cancer
Chemotherapy
Regimen
Pharmacology
Internal medicine
Medicine
Cyclophosphamide/Thalidomide
Thalidomide
low dose
chemotherapy resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations